Early Tx doesn't reduce risk for congenital toxoplasmosis
Even though some European countries have been screening prenatally for congenital toxoplasmosis for about 30 years, authors of a systematic review of cohort studies on the subject say it is unclear whether early treatment significantly reduces risk for the infection in newborns.
Even though some European countries have been screening prenatally for congenital toxoplasmosis for about 30 years, authors of a systematic review of cohort studies on the subject say it is unclear whether early treatment significantly reduces risk for the infection in newborns.
Researchers included 26 studies in the meta-analysis. They calculated an adjusted odds ratio (OR 0.48; P=0.05) for mother-to-child transmission when treatment was started prenatally within 3 weeks of seroconversion versus when treatment was started after 8 or more weeks. And prenatal treatment did not significantly reduce the risk of clinical manifestations in infected live-born infants (adjusted OR for treated vs. untreated 1.11).
The researchers also found that increasing gestational age at seroconversion was associated with increased risk of mother-to-child transmission (OR 1.15) and decreased risk of intracranial lesions (0.91), but not with eye lesions (0.97).
